Johnson & Johnson (JNJ) Gains from Sales and Divestitures (2010 - 2012)
Johnson & Johnson (JNJ) posted Gains from Sales and Divestitures of $8.3 million for Q1 2012, up 31.81% sequentially from $6.3 million in Q1 2011, and up 31.81% YoY from $6.3 million in Q1 2011.
Johnson & Johnson (JNJ) Gains from Sales and Divestitures (2010 - 2012) Analysis & Trends
Johnson & Johnson (JNJ) has 3 years of Gains from Sales and Divestitures data on file, last reported at $8.3 million in Q1 2012.
- Quarterly Gains from Sales and Divestitures rose 31.81% year-over-year to $8.3 million in Q1 2012, while the trailing twelve-month figure through Jan 2012 was $8.3 million (up 31.81% YoY) and the FY2012 annual result came in at $8.3 million, up 31.81% from the prior year.
- Gains from Sales and Divestitures grew to $8.3 million in Q1 2012 per JNJ's latest filing, from $6.3 million in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $8.3 million in Q1 2012, with the low at $5.7 million in Q1 2010.
- Average Gains from Sales and Divestitures over 3 years is $6.8 million, with a median of $6.3 million recorded in 2011.
- Year-over-year, Gains from Sales and Divestitures gained 10.2% in 2011 and jumped 31.81% in 2012.
- Johnson & Johnson's Gains from Sales and Divestitures stood at $5.7 million in 2010, then gained by 10.2% to $6.3 million in 2011, then soared by 31.81% to $8.3 million in 2012.
- Business Quant data shows JNJ's Gains from Sales and Divestitures at $8.3 million in Q1 2012, $6.3 million in Q1 2011, and $5.7 million in Q1 2010.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 1, 2012 | 8.30 Mn |
| Jan 1, 2012 | 8.30 Mn |
| Jan 2, 2011 | 6.30 Mn |
| Jan 2, 2011 | 6.30 Mn |
| Jan 3, 2010 | 5.71 Mn |
| Jan 3, 2010 | 5.71 Mn |